S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

IPA ImmunoPrecise Antibodies Ltd

0.50

-0.008 (-1.57%)

Feb 07 2025 - Closed

Delayed by 15 minutes

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more ImmunoPrecise Antibodies Charts.

ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more ImmunoPrecise Antibodies Charts.

ImmunoPrecise Antibodies Ltd News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 3 February 2025 (5 days ago) • Edgar (US Regulatory)

ImmunoPrecise Antibodies (IPA) annonce la réalisation d'un placement d'actions sur le marché et la conversion complète de la débenture de Yorkville
Monday 27 January 2025 (2 weeks ago) • Business Wire

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 27 January 2025 (2 weeks ago) • Edgar (US Regulatory)

ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture
Monday 27 January 2025 (2 weeks ago) • Business Wire

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 24 January 2025 (2 weeks ago) • Edgar (US Regulatory)

IPA (ImmunoPrecise Antibodies), pionnier des thérapies GLP-1 conçues par l'IA : Un nouveau chapitre potentiel en matière de traitement du diabète
Wednesday 22 January 2025 (2 weeks ago) • Business Wire

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Wednesday 22 January 2025 (2 weeks ago) • Edgar (US Regulatory)

IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment
Wednesday 22 January 2025 (3 weeks ago) • Business Wire

ImmunoPrecise Antibodies redéfinit sa stratégie de pipeline en faisant appel à l'IA et à l'innovation basée sur les principes premiers pour la découverte de médicaments
Friday 17 January 2025 (3 weeks ago) • Business Wire

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Friday 17 January 2025 (3 weeks ago) • Edgar (US Regulatory)

ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation
Friday 17 January 2025 (3 weeks ago) • Business Wire

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Friday 3 January 2025 (1 month ago) • Edgar (US Regulatory)

More ImmunoPrecise Antibodies Ltd News Articles

Vontobel Financial Produ...

Spotify Technology

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions